"name","label","description","id","rationale","instanceType","uuid:ID"
"Study Design 1","","The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","67855ca4-85b3-4373-8514-99b928e3d4b4"
